Back to School: How biopharma can reboot drug development. Access exclusive analysis here

NGM pops on additional Phase II NASH data for aldafermin

Positive histology data helped NGM snap a losing streak for NASH therapies and lifted the biotech’s stock on a day where the sector and broader markets saw mostly red.

Shares of NGM Biopharmaceuticals Inc. (NASDAQ:NGM) gained as much as 42% Monday after once-daily aldafermin (NGM282) 1 mg showed a statistically significant improvement on the secondary composite endpoint of fibrosis improvement and resolution of non-alcoholic steatohepatitis, with 22% of aldafermin-treated patients achieving

Read the full 700 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers